TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in <i>BRAF-</i> Mutant Melanoma
Ryan B. Corcoran(Massachusetts General Hospital), Jeffrey A. Engelman(Cancer Research Center), Keith T. Flaherty(Cancer Research Center), Daniel Winokur(Harvard University), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Daniel A. Haber(Howard Hughes Medical Institute), Anthony C. Faber(Virginia Commonwealth University), Rosalynn M. Nazarian(Harvard University), Shyamala Maheswaran(Massachusetts General Hospital), Mari Mino–Kenudson(Massachusetts General Hospital), Jeffrey Settleman(Enzo Life Sciences (United States)), Aaron N. Hata(Harvard University), John R. Walsh(Massachusetts General Hospital), Jason T. Godfrey(University of Pennsylvania), Adriano Piris(Brigham and Women's Hospital), Ronald D. Brown(Massachusetts General Hospital), S. Michael Rothenberg(Pfizer (United States))
Cited by 138
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k